These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25556954)

  • 21. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
    Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
    Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.
    van Schaik IN; Winer JB; de Haan R; Vermeulen M
    Lancet Neurol; 2002 Dec; 1(8):491-8. PubMed ID: 12849334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of chronic inflammatory demyelinating polyradiculoneuropathy(CIDP)--a review].
    Mezaki T; Kaji R
    No To Shinkei; 2000 Dec; 52(12):1063-9. PubMed ID: 11193538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current treatments of chronic immune-mediated demyelinating polyneuropathies.
    Brannagan TH
    Muscle Nerve; 2009 May; 39(5):563-78. PubMed ID: 19301378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
    Bunschoten C; Jacobs BC; Van den Bergh PYK; Cornblath DR; van Doorn PA
    Lancet Neurol; 2019 Aug; 18(8):784-794. PubMed ID: 31076244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.
    Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P;
    Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients.
    Debs R; Reach P; Cret C; Demeret S; Saheb S; Maisonobe T; Viala K
    Int J Neurosci; 2017 Oct; 127(10):864-872. PubMed ID: 27918219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
    Racosta JM; Sposato LA; Kimpinski K
    Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
    Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
    Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measuring disease activity and clinical response during maintenance therapy in CIDP: from ICE trial outcome measures to future clinical biomarkers.
    Katzberg HD; Latov N; Walker FO
    Neurodegener Dis Manag; 2017 Apr; 7(2):147-156. PubMed ID: 28112008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous vs. intravenous immunoglobulin in CIDP: pharmacokinetic and clinical response.
    Cocito D; Romagnolo A; Peci E; Rosso M; Lopiano L; Milla P; Merola A
    J Peripher Nerv Syst; 2016 Jun; 21(2):114-6. PubMed ID: 27251938
    [No Abstract]   [Full Text] [Related]  

  • 32. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice.
    Press R; Hiew FL; Rajabally YA
    Acta Neurol Scand; 2016 Apr; 133(4):228-38. PubMed ID: 26437234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
    Chan YC; Allen DC; Fialho D; Mills KR; Hughes RA
    J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):114-6. PubMed ID: 16361609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Cocito D; Paolasso I; Antonini G; Benedetti L; Briani C; Comi C; Fazio R; Jann S; Matà S; Mazzeo A; Sabatelli M; Nobile-Orazio E;
    Eur J Neurol; 2010 Feb; 17(2):289-94. PubMed ID: 19863650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic inflammatory demyelinating polyneuropathy: a treatment protocol proposal.
    Odaka M
    Expert Rev Neurother; 2006 Mar; 6(3):365-79. PubMed ID: 16533141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Seow H; Wilson P
    J Peripher Nerv Syst; 2006 Dec; 11(4):325-9. PubMed ID: 17117941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous immunoglobulin: a first-line treatment in CIDP?
    Vermeulen M
    Lancet Neurol; 2008 Feb; 7(2):115-6. PubMed ID: 18178526
    [No Abstract]   [Full Text] [Related]  

  • 38. Childhood acute and chronic immune-mediated polyradiculoneuropathies.
    Rabie M; Nevo Y
    Eur J Paediatr Neurol; 2009 May; 13(3):209-18. PubMed ID: 18585069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
    Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Afzal S
    J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.